
Bristol-Myers Squibb’s cardiovascular development leader discusses the importance of diversifying clinical trials for better patient outcomes.
Christen Harm is Pharmaceutical Executive's Associate Editor. Email her at charm@mmhgroup.com
Published: September 1st 2019 | Updated: